Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Common Eye Conditions
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. ( AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has filed a provision patent application with the U.S. Patent and Trademark Office on an innovative new rapid ophthalmological diagnostic solution designed to reliably measure both Ocular Immunoglobulin E (IgE) and MMP-9 in a single test. The test is slated for further clinical development in the first quarter of 2023 and, once FDA approved, will be added to AXIM’s expanding catalog of ophthalmological diagnostic tools available to clinicians throughout North America.
The first-of-its-kind test is designed to be administered at the point-of-care and will measure both IgE and MMP-9 levels in patients, rendering results in 10 minutes. Unlike other MMP-9 tests commercially available that require a tear sample from patients of up to ~10 microliters, AXIM’s new dual test will be able to measure both IgE and MMP-9 levels in a 20-2,000ng/mL using just a two microliter sample. This sample size significantly reduces patient discomfort in tear collection, where only one sample is needed to measure levels of both biomarkers. Additionally, other commercially available tests only provide a qualitative result (positive/negative) whereas AXIM’s new test measures actual levels of each biomarker, enabling clinicians to differentiate between the underlying causes of a patient’s eye condition and prescribe treatment accordingly and instantly at the point-of-care.
“This test is a revolution in the field of ophthalmological diagnostics, as it enables clinicians to more accurately diagnose and treat the millions of patients suffering from common eye conditions such as Dry Eye Disease (DED), which is commonly misdiagnosed and mistreated,” said John Huemoeller III, CEO of AXIM Biotechnologies. “This test was designed with clinicians in mind. For example, one of its key benefits is that it provides twice as much information to clinicians in a single test, versus the current standard that requires two separate tests. Given the amount of time clinicians are able to spend with patients and the number of patients seen in a given day, we foresee this as a major differentiator in the marketplace which will lead to increased adoption of our tests.”
Once developed and cleared, the test will be added to AXIM’s growing portfolio of FDA-cleared ophthalmological diagnostics tools, which includes rapid point-of-care tests for both IgE and Lactoferrin. The new combination test measures levels of matrix metalloproteinase, or MMP-9, in patient tear samples, along with IgE which is a key biomarker primarily associated with non-specific, allergic conjunctivitis, which often mimics Dry Eye Disease. MMP-9 is an enzyme that has been linked to signs of inflammation on the surface of the eye. This inflammation can be caused by a variety of indications including dry eye or chemical or mechanical damage to the eyes. The higher the level of MMP-9, the higher the degree of inflammation. Upon review of the results of the new test, clinicians will be able to prescribe either anti-inflammatory, antihistamine or both promptly during a patient’s visit, greatly increasing patient care and treatment outcomes.
According to the American Academy of Ophthalmology, approximately 20 million people in the United States (344 million people worldwide) have Dry Eye Disease, and that number is growing in both young and old adults, making it imperative that clinicians figure out how best to diagnose and treat it. According to the American Journal of Ophthalmology, as of July, 2017, a study reported an estimated 6 million people reported having experienced Dry Eye Disease symptoms but had never been diagnosed. AXIM’s diagnostic solutions seek to address this severely unmet clinical need and the addition of this test to AXIM’s portfolio only further positions the company as a leader in innovative ophthalmological diagnostic solutions.
For more information on AXIM’s diagnostic solutions or to speak with someone at AXIM’s commercialization partner Verséa about adding these innovative solutions to your clinic, please visit:https://www.versea.com/divisions/ophthalmics/
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM, Financial) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com.
About Verséa Holdings, Inc.
Verséa Ophthalmic, LLC (“Verséa”), a subsidiary of Verséa Holdings, Inc. headquartered in Tampa, FL, is a U.S. healthcare company founded by experienced business executives and prominent scientific medical experts, all committed to transforming scientific discoveries into applicable healthcare and wellness solutions that are critical to improving patients’ lives. To learn more, visit: www.versea.com.
Forward-Looking Statements
The statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim’s eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2022, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
CONTACT
Kyle Porter
CMW Media
P. 858-221-8001
[email protected]
AXIM Corporate
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422
Investor Relations
[email protected]
888-759-0844
SAN DIEGO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. ( AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has filed a provision patent application with the U.S. Patent and Trademark Office on an innovative new rapid ophthalmological diagnostic solution designed to reliably measure both Ocular Immunoglobulin E (IgE) and MMP-9 in a single test. The test is slated for further clinical development in the first quarter of 2023 and, once FDA approved, will be added to AXIM’s expanding catalog of ophthalmological diagnostic tools available to clinicians throughout North America.
The first-of-its-kind test is designed to be administered at the point-of-care and will measure both IgE and MMP-9 levels in patients, rendering results in 10 minutes. Unlike other MMP-9 tests commercially available that require a tear sample from patients of up to ~10 microliters, AXIM’s new dual test will be able to measure both IgE and MMP-9 levels in a 20-2,000ng/mL using just a two microliter sample. This sample size significantly reduces patient discomfort in tear collection, where only one sample is needed to measure levels of both biomarkers. Additionally, other commercially available tests only provide a qualitative result (positive/negative) whereas AXIM’s new test measures actual levels of each biomarker, enabling clinicians to differentiate between the underlying causes of a patient’s eye condition and prescribe treatment accordingly and instantly at the point-of-care.
“This test is a revolution in the field of ophthalmological diagnostics, as it enables clinicians to more accurately diagnose and treat the millions of patients suffering from common eye conditions such as Dry Eye Disease (DED), which is commonly misdiagnosed and mistreated,” said John Huemoeller III, CEO of AXIM Biotechnologies. “This test was designed with clinicians in mind. For example, one of its key benefits is that it provides twice as much information to clinicians in a single test, versus the current standard that requires two separate tests. Given the amount of time clinicians are able to spend with patients and the number of patients seen in a given day, we foresee this as a major differentiator in the marketplace which will lead to increased adoption of our tests.”
Once developed and cleared, the test will be added to AXIM’s growing portfolio of FDA-cleared ophthalmological diagnostics tools, which includes rapid point-of-care tests for both IgE and Lactoferrin. The new combination test measures levels of matrix metalloproteinase, or MMP-9, in patient tear samples, along with IgE which is a key biomarker primarily associated with non-specific, allergic conjunctivitis, which often mimics Dry Eye Disease. MMP-9 is an enzyme that has been linked to signs of inflammation on the surface of the eye. This inflammation can be caused by a variety of indications including dry eye or chemical or mechanical damage to the eyes. The higher the level of MMP-9, the higher the degree of inflammation. Upon review of the results of the new test, clinicians will be able to prescribe either anti-inflammatory, antihistamine or both promptly during a patient’s visit, greatly increasing patient care and treatment outcomes.
According to the American Academy of Ophthalmology, approximately 20 million people in the United States (344 million people worldwide) have Dry Eye Disease, and that number is growing in both young and old adults, making it imperative that clinicians figure out how best to diagnose and treat it. According to the American Journal of Ophthalmology, as of July, 2017, a study reported an estimated 6 million people reported having experienced Dry Eye Disease symptoms but had never been diagnosed. AXIM’s diagnostic solutions seek to address this severely unmet clinical need and the addition of this test to AXIM’s portfolio only further positions the company as a leader in innovative ophthalmological diagnostic solutions.
For more information on AXIM’s diagnostic solutions or to speak with someone at AXIM’s commercialization partner Verséa about adding these innovative solutions to your clinic, please visit:https://www.versea.com/divisions/ophthalmics/
About AXIM® Biotechnologies
Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM, Financial) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dye Eye Disease. For more information, please visit www.AXIMBiotech.com.
About Verséa Holdings, Inc.
Verséa Ophthalmic, LLC (“Verséa”), a subsidiary of Verséa Holdings, Inc. headquartered in Tampa, FL, is a U.S. healthcare company founded by experienced business executives and prominent scientific medical experts, all committed to transforming scientific discoveries into applicable healthcare and wellness solutions that are critical to improving patients’ lives. To learn more, visit: www.versea.com.
Forward-Looking Statements
The statements made by Axim Biotechnologies Inc., in this press release may be “forward-looking” in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim’s eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company’s diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim’s SEC reports and filings, including our Annual Report on Form 10-K filed on April 15, 2022, and other reports we file with the SEC, which are available at www.sec.gov. Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law.
CONTACT
Kyle Porter
CMW Media
P. 858-221-8001
[email protected]
AXIM Corporate
6191 Cornerstone Ct., Ste. 114
San Diego, CA 92121, USA
P. 858-923-4422
Investor Relations
[email protected]
888-759-0844
